Figure 5: CD200 knockdown and overexpression assays. | Scientific Reports

Figure 5: CD200 knockdown and overexpression assays.

From: CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors

Figure 5

(A) Relative CD200 mRNA levels of CAF608 cultures transfected with either control vector (sh Luc), sh CD200-1 or -2. (B) CD200 protein levels of CAF608, CAF608 sh Luc, sh CD200-1 and -2 cells. (C) The percent of control of viable PC9-mRFP cells after gefitinib treatment of cocultures consisting of PC9-mRFP and CAF608 sh Luc, CAF608 sh CD200 -1 or CAF608 sh CD200-2 cells. (D) Numbers of CAF608 cells transfected with sh Luc, sh CD200-1 or -2 after gefitinib administration. (E) Infection efficacy of lentiviruses as determined by FACS analysis (X axis: FL-4H, Y axis: FSC-H). (F) The percent of control of viable PC9-mRFP cells observed after gefitinib treatment of PC9-mRFP cultured alone or cocultured with either CAF621-Control or CAF621-CD200+(overexpressing of CD200) cells.

Back to article page